Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for thyroid
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. 24768112 2014 07 28 2014 08 19 2016 12 15 1474-547X 384 9940 2014 Jul 26 Lancet (London, England) Lancet Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. 319-28 10.1016/S0140-6736(14)60421-9 S0140-6736(14)60421-9 Patients with radioactive iodine (...) ((131)I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis because of the absence of effective treatment options. In this study, we assessed the efficacy and safety of orally administered sorafenib in the treatment of patients with this type of cancer. In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (DECISION), we investigated sorafenib (400 mg orally twice daily) in patients with radioactive iodine-refractory locally
Selenium supplementation for Hashimoto's thyroiditis. BACKGROUND: Hashimoto's thyroiditis is a common auto-immune disorder. The most common presenting symptoms may include anxiety, negative mood, depression, dry skin, cold intolerance, puffy eyes, muscle cramps and fatigue, deep voice, constipation, slow thinking and poor memory. Clinical manifestations of the disease are defined primarily by low levels of thyroid hormones; therefore it is treated by hormone replacement therapy, which usually (...) consists of levothyroxine (LT4). Selenium might reduce antibody levels and result in a decreased dosage of LT4 and may provide other beneficial effects (e.g. on mood and health-related quality of life). OBJECTIVES: To assess the effects of selenium supplementation on Hashimoto's thyroiditis. SEARCH METHODS: We searched the following databases up to 2 October 2012: CENTRAL in The Cochrane Library (2012, Issue 10), MEDLINE, EMBASE, and Web of Science; we also screened reference lists of included studies
Rituximab for thyroid-associated ophthalmopathy. BACKGROUND: Thyroid associated ophthalmopathy (TAO) is the most frequent extrathyroidal manifestation of Graves' disease, affecting up to 50% of patients, and has a great impact on quality of life. Rituximab is a human/murine chimeric monoclonal antibody that targets CD20, a transmembrane protein expressed on the surface of pre-B and mature B lymphocytes, but not on stem cells, pro-B lymphocytes or plasma cells. Preliminary work has shown
BRAF p.Val600Glu testing in papillary thyroid carcinoma BRAF p.Val600Glu testing in papillary thyroid carcinoma BRAF p.Val600Glu testing in papillary thyroid carcinoma Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation BRAF p.Val600Glu testing in papillary thyroid carcinoma. Lansdale: HAYES, Inc.. Genetic Testing Publication. 2013 Authors' conclusions The incidence (...) of thyroid carcinoma is rising steadily; in the United States, approximately 48,000 new cases were diagnosed and 1700 deaths were attributed to the disease in 2011. While thyroid cancer occurs more in women, it is more often fatal in men, and it is more common in whites than in blacks. Thyroid carcinoma is categorized into 3 histological types: differentiated, medullary, and anaplastic. A subtype of differentiated thyroid carcinoma, papillary thyroid carcinoma (PTC), comprised 80% of all treated thyroid
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. IMPORTANCE: BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-related patient mortality has not been established. OBJECTIVE: To investigate the relationship between BRAF V600E mutation and PTC-related mortality. DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of 1849 patients (1411 women and 438 men) with a median age of 46 years (interquartile range
Progress in molecular-based management of differentiated thyroid cancer. Substantial developments have occurred in the past 5-10 years in clinical translational research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules. BRAF mutation is a prognostic genetic marker that has improved risk stratification and hence tailored (...) management of patients with thyroid cancer, including those with conventionally low risks. Novel molecular-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials; such treatments are likely to become a component of the standard treatment regimen for patients with thyroid cancer in the near future. These novel molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting developments
Afirma® thyroid FNA analysis Afirma® thyroid FNA analysis Afirma® thyroid FNA analysis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Afirma® thyroid FNA analysis. Lansdale: HAYES, Inc.. Genetic Testing Publication. 2012 Authors' conclusions Thyroid nodules are discrete masses present in the thyroid gland that are a common clinical finding among adults (...) in the general population. Approximately 5% of women and 1% of men have a palpable thyroid nodule on physical examination, while up to 67% of adults may have thyroid nodules detected with a high-resolution ultrasound. The evaluation of thyroid nodules, which may represent benign lesions or malignant thyroid tumors, typically includes a cytopathological examination of a biopsy specimen obtained by fine-needle aspiration (FNA). Thyroid nodules are subsequently classified based on cytology, with 70% to 75
Thyroid hormone receptor beta (THRB) gene testing in resistance to thyroid hormone (RTH) Thyroid hormone receptor beta (THRB) gene testing in resistance to thyroid hormone (RTH) Thyroid hormone receptor beta (THRB) gene testing in resistance to thyroid hormone (RTH) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Thyroid hormone receptor beta (THRB) gene testing (...) in resistance to thyroid hormone (RTH) Lansdale: HAYES, Inc.. Genetic Testing Publication. 2012 Authors' conclusions Resistance to thyroid hormone (RTH) is an endocrine disorder characterized by reduced tissue responsiveness to circulating thyroid hormone. The condition, which is estimated to occur in approximately 1 in 40,000 individuals, may be diagnosed in patients with elevated levels of the thyroid hormones thyroxine (T4) and triiodothyronine (T3), along with normal to high levels of thyroid
The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: a meta-analysis The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: a meta-analysis The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: a meta-analysis Wu LM, Gu HY, Qu XH (...) , Zheng J, Zhang W, Yin Y, Xu JR CRD summary This review concluded that real-time ultrasonography was a good technique for preoperative lymph node staging of papillary thyroid carcinoma. Relevant studies may have been missed and there were limitations in the meta-analysis. The conclusions appear optimistic; summary estimates seemed to indicate that ultrasonography may be useful to confirm cervical lymph node metastases but not adequate for rule-out. Authors' objectives To assess the diagnostic
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. BACKGROUND: Metastatic thyroid cancers that are refractory to radioiodine (iodine-131) are associated with a poor prognosis. In mouse models of thyroid cancer, selective mitogen-activated protein kinase (MAPK) pathway antagonists increase the expression of the sodium-iodide symporter and uptake of iodine. Their effects in humans are not known. METHODS: We conducted a study to determine whether the MAPK kinase (MEK) 1 and MEK2 (...) inhibitor selumetinib (AZD6244, ARRY-142886) could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer. After stimulation with thyrotropin alfa, dosimetry with iodine-124 positron-emission tomography (PET) was performed before and 4 weeks after treatment with selumetinib (75 mg twice daily). If the second iodine-124 PET study indicated that a dose of iodine-131 of 2000 cGy or more could be delivered to the metastatic lesion or lesions, therapeutic radioiodine
Population-Based Study Evaluating and Predicting the Probability of Death Resulting From Thyroid Cancer and Other Causes Among Patients With Thyroid Cancer 23270002 2013 01 28 2013 03 11 2013 01 28 1527-7755 31 4 2013 Feb 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. 468-74 (...) 10.1200/JCO.2012.42.4457 The purpose of this study was to evaluate the probability of death for patients with thyroid cancer and construct a comprehensive nomogram based on a competing risks model to predict cumulative incidence of death resulting from thyroid cancer, other cancers, and non-cancer-related causes. Patients diagnosed with thyroid cancer between 1988 and 2003 were selected for the study from the Surveillance, Epidemiology, and End Results program. We estimated probabilities of death
Thyroid hormones for acute kidney injury. BACKGROUND: Acute kidney injury (AKI), which is common in hospitalised patients, is associated with significant morbidity and mortality. Despite recent advances in treatment, AKI outcomes have not changed substantially during the past four decades, and incidence is increasing. There is an urgent need to explore novel therapeutic agents and revisit some older drugs to review their roles in the management of AKI. Although thyroid hormone therapy has shown (...) promise in experimental animal studies, clinical efficacy and safety have not been systematically assessed for the management of people with AKI. OBJECTIVES: To evaluate the benefits and harms of thyroid hormones for the treatment of hospitalised adults with AKI of any aetiology. SEARCH METHODS: We searched the Cochrane Renal Group's Specialised Register, CENTRAL, MEDLINE, and EMBASE. We also checked the reference lists of retrieved studies and articles.Date of search: November 2012 SELECTION CRITERIA
Improving Voice Outcomes After Thyroid Surgery SAGE Journals: Your gateway to world-class journal research MENU My Profile Institution Society Access Options You can be signed in via any or all of the methods shown below at the same time. My Profile Sign in here to access free tools such as favourites and alerts, or to access personal subscriptions Email (required) Password (required) Remember me I don't have a profile I am signed in as: With my free profile I can: Set up and register for List
Absolute Risk Prediction of Second Primary Thyroid Cancer Among 5-Year Survivors of Childhood Cancer 23169509 2012 12 31 2013 02 21 2016 10 19 1527-7755 31 1 2013 Jan 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Absolute risk prediction of second primary thyroid cancer among 5-year survivors of childhood cancer. 119-27 10.1200/JCO.2012.41.8996 We developed three absolute risk models for second primary thyroid cancer to assist (...) with long-term clinical monitoring of childhood cancer survivors. We used data from the Childhood Cancer Survivor Study (CCSS) and two nested case-control studies (Nordic CCSS; Late Effects Study Group). Model M1 included self-reported risk factors, model M2 added basic radiation and chemotherapy treatment information abstracted from medical records, and model M3 refined M2 by incorporating reconstructed radiation absorbed dose to the thyroid. All models were validated in an independent cohort of French
The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. OBJECTIVES: To examine the risk of atrial fibrillation in relation to the whole spectrum of thyroid function in a large cohort of patients. DESIGN: Population based cohort study of general practice patients identified by linkage of nationwide registries at the individual level. SETTING: Primary care patients in the city of Copenhagen. SUBJECTS: Registry data for 586,460 adults who had (...) their thyroid function evaluated for the first time by their general practitioner during 2000-10 and who were without previously recorded thyroid disease or atrial fibrillation. MAIN OUTCOME MEASURE: Poisson regression models used to estimate risk of atrial fibrillation by thyroid function. RESULTS: Of the 586,460 individuals in the study population (mean (SD) age 50.2 (16.9) years, 39% men), 562,461 (96.0%) were euthyroid, 1670 (0.3%) had overt hypothyroidism, 12,087 (2.0%) had subclinical hypothyroidism